Bimekizumab Maintains Safety, Efficacy in Ankylosing Spondylitis

Bimekizumab (Bimzelx, UCB) seems safe and effective for ankylosing spondylitis. Among 303 patients in the open-label extension of the BE AGILE trial, no new safety signals were identified and efficacy was sustained through three years.

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ